GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hikma Pharmaceuticals PLC (LSE:HIK) » Definitions » EV-to-Revenue

Hikma Pharmaceuticals (LSE:HIK) EV-to-Revenue : 2.21 (As of May. 01, 2024)


View and export this data going back to 2005. Start your Free Trial

What is Hikma Pharmaceuticals EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Hikma Pharmaceuticals's enterprise value is £5,035 Mil. Hikma Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was £2,274 Mil. Therefore, Hikma Pharmaceuticals's EV-to-Revenue for today is 2.21.

The historical rank and industry rank for Hikma Pharmaceuticals's EV-to-Revenue or its related term are showing as below:

LSE:HIK' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.61   Med: 3.25   Max: 5.62
Current: 2.21

During the past 13 years, the highest EV-to-Revenue of Hikma Pharmaceuticals was 5.62. The lowest was 1.61. And the median was 3.25.

LSE:HIK's EV-to-Revenue is ranked better than
51.61% of 1025 companies
in the Drug Manufacturers industry
Industry Median: 2.32 vs LSE:HIK: 2.21

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-01), Hikma Pharmaceuticals's stock price is £19.24. Hikma Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was £10.23. Therefore, Hikma Pharmaceuticals's PS Ratio for today is 1.88.


Hikma Pharmaceuticals EV-to-Revenue Historical Data

The historical data trend for Hikma Pharmaceuticals's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hikma Pharmaceuticals EV-to-Revenue Chart

Hikma Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.97 3.59 2.84 2.05 2.08

Hikma Pharmaceuticals Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.84 - 2.05 - 2.08

Competitive Comparison of Hikma Pharmaceuticals's EV-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Hikma Pharmaceuticals's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hikma Pharmaceuticals's EV-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Hikma Pharmaceuticals's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Hikma Pharmaceuticals's EV-to-Revenue falls into.



Hikma Pharmaceuticals EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Hikma Pharmaceuticals's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=5035.081/2274.104
=2.21

Hikma Pharmaceuticals's current Enterprise Value is £5,035 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Hikma Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was £2,274 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Hikma Pharmaceuticals  (LSE:HIK) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Hikma Pharmaceuticals's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=19.24/10.227
=1.88

Hikma Pharmaceuticals's share price for today is £19.24.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Dec. 2023 was £10.23.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Hikma Pharmaceuticals EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Hikma Pharmaceuticals's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Hikma Pharmaceuticals (LSE:HIK) Business Description

Traded in Other Exchanges
Address
1 New Burlington Place, London, GBR, W1S 2HR
Hikma Pharmaceuticals PLC is engaged in the development, manufacture, and marketing of a broad range of generic, branded, and in-licensed pharmaceutical products. The firm operates in three segments: injectables, generics, and branded. The majority of the company's sales are based in the U.S. and to a lesser degree in the Middle East, North Africa, and Europe.

Hikma Pharmaceuticals (LSE:HIK) Headlines

No Headlines